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Monoclonal antibodies against 12 of the 17 IATS serotype strains ofPseudomonas aeruginosa were produced.
Eighty-seven hybridoma clones were isolated, and the antibodies secreted were found to be reactive with both
Formalin-fixed whole cells and purified lipopolysaccharide of homologous strains in enzyme-linked immuno-
sorbent assays. Among these monoclonal antibodies, the predominant antibody class was immunoglobulin M
(IgM) (76%), although antibodies of the IgG2a and IgG3 isotypes were also produced. The monoclonal
antibodies could further be divided intQ two groups based on their ability to agglutinate whole cells of
homologous strains. The agglutinating monoclonal antibodies were found to immunoblot with the 0 side chains
of homologous lipopolysaccharide, while the nonagglutinating monoclonal antibodies were found to be reactive
with outer membrane protein-associated lipopolysaccharide. The applicability of monoclonal antibodies for
serotyping was examined, and several antibodies were found to agglutinate whole cells and immunoblot with
the 0 antigen of corresponding serotypes of clinical isolates from cystic fibrosis patients. In conclusion, a set
of monoclonal antibodies against the IATS serotype strains of P. aeruginosa have been produced. These
antibodies represent a bank of invaluable immunological reagents which may have application in serotyping,
epitope mapping, Iipopolysaccharide structural determination, and studies of protection against P. aeruginosa.
The differences among the 0 antigen side chains of lipo-
polysaccharide (LPS) of Pseudomonas aeruginosa form the
basis of the serotyping system for this organism. Due to the
existence of a relatively large number of such systems
established by various investigators around the world, a
standardized serotyping system known as the International
Antigenic Typing Scheme (IATS) consisting of 17 standard
0-antigenic serotypes has been proposed (3, 28). To com-
plement this proposed scheme, commercial antisera against
each of the 17 0 types were produced by Difco Laboratories
(Detroit, Mich.). In most epidemiological studies, more than
90% of clinical isolates can usually be allocated to a specific
O type (3, 42) by means of the standard slide or tube
agglutination method. However, difficulties can still be en-
countered when a small number of strains agglutinate with
more than one antiserum even when the sera have been
absorbed (28). This and other major typing problems are
illustrated by P. aeruginosa isolates from cystic fibrosis
patients. These strains are often difficult to serotype and are
classified as nontypable since they either do not type with
any typing sera, autoagglutinate, or polyagglutinate with
more than one 0 antigen-specific typing serum (16, 32, 35,
40, 43). These abnormal typing patterns, occurring in up to
60% of cystic fibrosis isolates, were found by Hancock et al.
(16) to correlate with deficiencies in the amount of 0 antigen
in the LPS of these strains. The above-mentioned limitations
of the existing serotyping system for P. aeruginosa warrant
the development of monoclonal antibodies (MAbs) with
improved specificity of interaction with each serotype.
MAbs, with their obvious advantages over polyclonal
sera, including availability, specificity, and reproducibility,
are gradually replacing rabbit antibodies as the immunolog-
ical reagent of choice for serotyping and the analysis of
bacterial cell surface antigens (25, 35). Joly et al. (19) have
produced MAbs specific for serogroups 1 to 6 of Legionella
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pneumophila. Others have used MAbs to type Neisseria
gonorrhoeae (53) and Neisseria meningitidis (52). More
recently, Moll et al. (33) have produced an MAb against
Escherichia coli 01 LPS which reacts with the LPS of O1A
and OlAl strains but not with O1B or O1C strains in
Western blotting experiments. Monoclonal antibodies have
also been produced against the LPS of a wide variety of
gram-negative organisms, including Chlamydia spp. (6),
Shigella flexneri (7), Brucella abortus and Yersinia entero-
colitica (4), Escherichia coli (20, 22, 41), Haemophilus
influenzae type b (21), and Vibrio cholerae group 0:1 (14).
These MAbs were used either for mapping common epitopes
from one strain to the next, for subtyping strains in the same
serogroup, or for correlating the immunological relatedness
of LPS to structural studies. Due to the importance of LPS
as a virulence factor (9, 10) and a major protective antigen in
the pseudomonal extract vaccine (29, 30), much effort has
been expended in the production of MAbs against LPS
antigens of this organism. Hancock et al. (17) have produced
MAbs against both the 0-antigen and the rough core of strain
PAO1, while Barclay et al. (2) reported the production of 18
MAbs against the protective LPS antigen of IATS 01
strains. Sawada et al. (47, 48) have produced both mouse and
human MAbs (49) against the LPS of a few serotypes of P.
aeruginosa. At a P. aeruginosa symposium held in
Vancouver, British Columbia, Sadoff et al. (46) reported the
production of both type-specific MAbs and a panel of 11
MAbs which exhibited broad cross-reactivity with Fisher
immunotype strains and IATS serotype strains. More re-
cently, Stoll et al. (51) have described an MAb specific for
the 0 antigen of the Fisher immunotype 1. Thus far, a
systematic approach to produce MAbs against each IATS 0
serotype strain has not been attempted. In this study, we
report the production and characterization of a bank of
MAbs against the LPS of IATS serotype strains of P.
aeruginosa. We also assess the potential of these MAbs as
serotyping reagents.
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(Parts of this work were presented at the 36th Annual
Meeting of the Canadian Society of Microbiologists,
Toronto, Ontario, June 1986, abstract IN14.)
MATERIALS AND METHODS
Bacterial strains and growth conditions. P. aeruginosa
PAO1 strain H103 of 0 serotype 5 (IATS) (17, 26) and a
complete set of IATS serotype-specific strains were used for
the isolation of LPS and outer membrane and for Formalin
fixation of the whole-cell immunogen. The complete set of
IATS serotype strains used was type 01 (ATCC 33348), type
02 (ATCC 33349), type 03 (ATCC 33350), type 04 (ATCC
33351), type 05 (ATCC 33352), type 06 (ATCC 33354), type
07 (ATCC 33353), type 08 (ATCC 33355), type 09 (ATCC
33356), type 010 (ATCC 33357), type 011 (ATCC 33358),
type 012 (ATCC 33359), type 013 (ATCC 33360), type 014
(ATCC 33361), type 015 (ATCC 33362), type 016 (ATCC
33363), and type 017 (ATCC 33364). In addition, clinical
isolates from cystic fibrosis patients obtained from D.
Speert, Children's Hospital, Vancouver, were used to ex-
amine the serotyping abilities of MAbs. These clinical strains
were typed with P. aeruginosa typing sera (Difco) and
separated into four serogroups (01, 05, 06, and 09). The
serotype 01 strains included CF433C, CF381C, CF655M,
CF566C, CF395C, CF512M and CF376M; the serotype 05
strains included CF154C, CF461C, CF81M, CF681C,
CF632M, and CF617C; the serotype 06 group included
strains CF312R, CF538C, CF144C, CF27M, CF55C,
CF651M, CF230M, CF511C, and CF285M; and the two
serotype 09 strains were CF127C and CF305M.
P. aeruginosa cultures were maintained on 1% (wt/vol)
proteose peptone no. 2 (PP2) agar (Difco). Fresh colonies
were picked from overnight cultures on PP2 agar plates for
agglutination tests. For antigen preparation, colonies were
grown in PP2 broth until the ODwo was approximately 0.5 to
0.8 (26).
Outer membrane and LPS isolation techniques. Outer
membranes were isolated by the one-step sucrose gradient
method of Hancock and Carey (15). The method of LPS
extraction used was exactly as described by Darveau and
Hancock (12). LPS prepared by this method was subse-
quently used as the antigen for screening hybridomas secret-
ing LPS-specific MAbs. The procedure of Hitchcock and
Brown (18) was followed to prepare LPS of clinical isolates
in Western blotting experiments.
Hybridoma production. Female BALB/c mice (8 to 10
weeks old; Charles River Canada Inc., St.-Constant, Que-
bec) were immunized intraperitoneally with 0.2 ml of a 1:1
mixture of 107 Formalin-fixed P. aeruginosa cells and
Freund incomplete adjuvant (Difco). An intraperitoneal
booster immunization with the same immunogen was given
on day 12. A third booster with 0.1 ml of 107 Formalin-fixed
bacterial cells was given 1 week later via the tail vein. The
mice were sacrificed 4 days later, and their spleens were
removed. The fusion between primed spleen cells and the
NS-1 myeloma cells to produce hydridomas was performed
as described by Oi and Herzenberg (36) but with slight
modifications. The fusogen used consisted of 40% polyeth-
ylene glycol (Mr, 1,300 to 1,600; Sigma Chemical Co., St.
Louis, Mo.) with 4% dimethyl sulfoxide (Sigma) (27) in
supplemented Dulbecco modified Eagle medium (DMEM)
without fetal bovine serum.
Selection and cloning of hybridomas. At approximately 10
to 14 days postfusion, large colonies of growing hybridoma
clones were highly visible in 24-well tissue culture plates
(Linbro, Flow Laboratories, Mississauga, Ontario). To
speed up our selection and screening process, these visible
colonies were transferred to 96-well tissue culture plates
(Linbro) by sterile Pasteur pipettes and allowed to grow for
24 to 48 h in DMEM supplemented with 20% fetal bovine
serum, 100 ,uM hypoxanthine, and 16 ,uM thymidine. En-
zyme-linked immunosorbent assay (ELISA) was performed
by the method of Mutharia and Hancock (34) with slight
modifications, and a bacterial slide agglutination test was
used to assay the reactivities of the culture supernatants
against P. aeruginosa LPS. In the ELISA, the antigen used
was 107 Formalin-fixed bacterial cells or 0.5 ,ug of LPS
diluted in carbonate buffer (55). Also, 1.5% gelatin (Sigma)
was used instead of bovine serum albumin as the blocking
agent. The slide agglutination test was performed by mixing
10 ,u1 of the culture supernatant with 10 p.l of a bacterial
suspension containing 1010 CFU/ml. Positive agglutinations
were usually apparent within 30 s. Cloning of positive
hybridomas by limiting dilution, storage of expanded hybrid-
omas, and enhanced antibody production in pristane
(2,6,10,14-tetramethylpentadecane; Sigma)-primed BALB/c
mice were performed essentially as described previously
(36). The class and subclass determination of the MAbs
produced was performed with an ELISA method and a
mouse typer kit (Bio-Rad Laboratories, Richmond, Calif.).
PAGE. The discontinuous sodium dodecyl sulfate-
polyacrylamide gel electrophoresis (SDS-PAGE) procedure
of Hancock et al. (16) with 14% running gels was used. Silver
staining of the LPS was done by the method of Hitchcock
and Brown (18).
Immunoblotting. The Western immunoblotting procedure
of Towbin et al. (54) as modified by Burnette et al. (5) was
used. From our experience, purified P. aeruginosa LPS does
not transfer as efficiently from the SDS-polyacrylamide gels
onto the nitrocellulose as outer membrane proteins. Since
outer membrane proteins were known to be closely associ-
ated with LPS molecules (45), outer membrane preparations
were also used to immunoblot with LPS-specific MAbs.
After reacting with MAbs, the nitrocellulose blots were
developed at room temperature by using a goat anti-mouse
F(ab')2 alkaline phosphatase-conjugated antibody (Helix
Biotech, Vancouver, British Columbia) and a substrate
consisting of 20 mg of TR fast red (Sigma) and 10 mng of
napthol AS-MX phosphate (Sigma) in 10 ml of 50 mM Tris
hydrochloride, pH 8.8.
Double immunodiffusion. The double-diffusion in gel
method was performed in 1% (wt/vol) agarose in Tris-
barbital buffer as described previously (26). The antigen
wells were filled with sonicated whole-cell antigens, and the
antibody wells were filled with undiluted or twofold dilutions
of hybridoma culture supernatants and ascitic fluid.
RESULTS
Isolation of LPS-specific hybridomas. From every fusion
experiment performed, hybridomas were identified consis-
tently in more than 70% of all the tissue culture wells. The
hybridomas secreted antibodies that reacted with Formalin-
fixed whole-cell antigens of homologous P. aeruginosa
strains when assayed by ELISA. However, only those
hybrids secreting MAbs that also reacted with purified LPS
of the same strain were selected and expanded for cloning
and antibody production by the ascites method. A total of 87
clones (of more than 4,000 hybrids) were isolated and
characterized. The culture supernatants of these hybridomas
were highly reactive with 0.5 ,ug of LPS when assayed by
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TABLE 1. Characterization of MAbs against serotype strains
of P. aeruginosa
MAIoyeHomologous tLogloMAb, 0 specificitya~ Isotype Homologousio ELISAagg utination titerb
MF25-1
MF25-2
MF25-3
MF25-4
MF25-5
MF25-6
MF27-1
MF27-2
MF27-3
MF5-1
MF5-2
MF5-3
MF5-4
MF57-1
MF57-2
MF57-3
MF57-4
MF57-5
MF57-6
MF57-7
MF57-8
MF57-9
MF57-10
01
01
01
01
01
01
02
02
02
03
03
03
03
03
03
03
03
03
03
03
03
03
03
IgM
IgM
IgM
IgM
IgM
IgM
IgG2b
IgM
IgG2b
IgG2b
IgM
IgM
IgM
NDc
ND
ND
IgM
IgM
ND
ND
IgM
IgM
ND
+
+
+
+
+
8
6
3
2
8
8
1
3
2
3
2
1
1
6
6
4
6
5
6
3
4
5
6
+
TABLE 1-Continued
MAHOomoloIagout n tLogloMAb 0 specificitya Isotype Homologousio E ISAagg utination titerb
MF30-1
MF30-2
MF30-3
MF30-4
MF30-5
MF30-6
MF30-7
MF43-1
MF43-2
MF43-3
MF43-4
MF43-5
MF43-6
MF43-7
MF43-8
MF43-9
MF54-1
MF54-2
MF54-3
MF54-4
MF54-5
08
08
08
08
08
08
08
09
09
09
09
09
09
09
09
09
010
010
010
010
010
MF55-1 011
MF50-1 011
IgM
IgG2b
IgM
IgM
IgM
IgG2b
IgM
IgM
IgM
IgM
IgM
IgM
IgM
IgM
IgM
IgM
IgM
IgM
IgM
IgM
IgM
IgM
IgM
+
+
+
+
+
4
3
7
4
8
4
2
3
3
5
8
3
3
3
3
4
4
3
ND
1
4
3
7
+
IgM
IgM
IgG2b
IgM
IgG2b
IgM
IgM
IgM
IgM
IgM
IgM
IgM
IgM
IgM
IgM
IgM
IgM
IgM
IgM
IgM
IgM
IgG3
IgM
ND
IgG2b
IgM
IgM
3 MF35-1
3 MF35-2
3 MF35-3
4 MF35-4
3 MF35-5
3 MF35-6
3 MF35-7
1 MF35-8
1
MF45-1
4 MF45-2
4 MF45-3
2 MF45-4
3 MF45-5
1 MF45-6
2
6
3
2
7
2
1
3
3
3
3
6
8
Continued on following column
ELISA (Table 1). The MAbs produced by these hybridomas
were subsequently judged to be monospecific from the
formation of a single precipitin band in Ouchterlony double-
diffusion tests against sonicated whole-cell extracts of the
homologous P. aeruginosa strains.
Characterization and interaction of MAbs with IATS
serotype strains of P. aeruginosa. The 87 MAbs were charac-
012
012
012
012
012
012
012
012
014
014
014
014
014
014
IgM
IgM
IgM
IgM
IgM
IgM
IgM
ND
ND
ND
IgM
ND
ND
IgM
3
3
3
4
5
3
3
2
2
3
4
4
4
a 0 specificity represented positive reactivity with the LPS of the desig-
nated 0 group in an ELISA.
b Log10 ELISA titer was determined as the highest serial 10-fold dilution of
the ascitic fluid that still gave an OD4o5 of -0.1 when reacted with 0.5 p.g of
LPS. Alkaline phosphatase and p-nitrophenyl-phosphate was the enzyme-
substrate system used.
c ND, Not determined.
terized for their 0 antigen specificity by both ELISA and
bacterial agglutination tests, and their immunoglobulin class
or subclass status was also determined (Table 1). These
MAbs could be separated into 12 groups according to the
serogroup of their original immunizing strain of P. aerugi-
nosa as well as the specific reactivity with LPS of the 17
IATS strains (Table 1). Sixty-six (76%) MAbs belonged to
the immunoglobulin M (IgM) class, while 8 (9%) belonged to
the IgG2b subclass. Interestingly, only 23 (35%) of the 66
IgM MAbs agglutinated with their homologous strains. Only
one of eight IgG2b MAbs agglutinated with its homologous
strain of bacteria, whereas the IgG3 MAb (MF23-1) readily
agglutinated the 06 strain of P. aeruginosa. MAbs specific
for the LPS of IATS 02, 04, 05, and 010 strains did not
agglutinate their homologous immunizing P. aeruginosa
strains. However, three of the eight MAbs raised against P.
MF31-1
MF31-2
MF31-3
MF31-4
MF31-5
MF31-6
MF31-7
MF31-8
MF31-9
MF32-1
MF32-2
MF32-3
MF32-4
MF13-1
MF13-2
MF15-1
MF15-2
MF15-3
MF15-4
MF15-5
MF19-1
MF23-1
MF23-2
MF23-3
MF23-4
MF29-1
MF29-2
04
04
04
04
04
04
04
04
04
05
05
05
05
05 (PA01)
05 (PA01)
05 (PAO1)
05 (PA01)
05 (PA01)
05 (PA01)
05 (PAO1)
05 (PAO1)
06
06
06
06
07
07
VOL. 55, 1987 1053
1054 LAM ET AL.
C D E
FIG. 1. SDS-PAGE and Western immunoblotting of LPS and
outer membrane antigens of P. aeruginosa. Lane A, Molecular
weight standards (indicated in thousands). Lane B, Coomassie
blue-stained outer membranes of strain PAO1 (15 ,ug of protein
sample was loaded); F, G, H2, and I are major outer membrane
protein designations. Lane C, silver-stained LPS of strain PAO1;
note the ladderlike 0 antigen bands and the low-molecular-weight
core region. Lane D, Immunoblot of outer membrane of strain
PAO1 with agglutinating MAb MF15-1; note the interaction with the
ladderlike bands, which is indicative of reactivity with 0 antigen.
Lane E, Immunoblot of outer membrane of strain PAO1 with
nonagglutinating MAb MF31-4; note the reactivity with major outer
membrane protein bands.
aeruginosa PAO1 (serotype 5) agglutinated readily with
PAO1 and other serotype 5 strains. Thus, we have produced
a bank of MAbs that can specifically agglutinate P. aerugi-
nosa strains of serotype 01, 03, 05, 06, 07, 08, 09, 011,
012, and 014.
Interaction of MAbs with LPS and outer membrane anti-
gens. All the MAbs listed in Table 1 reacted with Formalin-
fixed whole cells and LPS of their homologous strains of P.
aeruginosa. To determine the antigen specificity of these
antibodies, Western immunoblotting was performed with
both outer membrane and LPS as antigens. MAbs that were
found to agglutinate homologous strains blotted specifically
with the ladderlike bands on the nitrocellulose regardless of
whether the outer membrane or the LPS was used as the
antigen (Fig. 1D). This ladderlike banding pattern was char-
acteristic of the migration of 0 antigens in SDS-PAGE (Fig.
1C). Interaction between the rough core region of the
electrophoretically separated LPS and the agglutinating
MAbs was not observed in most cases. Only the 09-specific
MAb MF43-4 was found to blot the core as well as the 0
antigen portion of homologous LPS. In contrast, the nonag-
glutinating MAbs did not blot with any of the 0 side chain
bands when LPS was used as the blotting antigen (Fig. 1E).
It was intriguing to find, however, that the same antibodies
blotted with major outer membrane protein bands (Fig. 1B
and E), in particular, protein F (ca. 39 kilodaltons [kDa]),
protein H2 (ca. 21 kDa), and protein I (ca. 11 kDa) (nomen-
clature according to Hancock and Carey [15]), when outer
membrane was used as the blotting antigen.
Interaction of MAbs with heterologous strains among the
IATS strains. A large number of cross-reacting groups have
been described in previous studies when the 01-017 strains
of IATS P. aeruginosa are tested with the Difco commercial
TABLE 2. Interaction of MAbs with typable clinical isolates of
P. aeruginosa from cystic fibrosis patients
Bacterial Serogroup MAb used Agglutination Immunoblotbstraina
IATS 01 01 MF25-3 + 0-Ag
CF433C 01 MF25-3 + 0-Ag
CF381C 01 MF25-3 + 0-Ag
CF655M 01 MF25-3 + 0-Ag
CF566C 01 MF25-3 + 0-Ag
CF395C 01 MF25-3 + 0-Ag
CF512M 01 MF25-3 + 0-Ag
CF376M 01 MF25-3 + 0-Ag
IATS 06 06 MF23-2 + 0-Ag
CF312R 06 MF23-2 + NR
CF538C 06 MF23-2 + NR
CF144C 06 MF23-2 + NR
CF27M 06 MF23-2 + NR
CF55C 06 MF23-2 + 0-Ag
CF651M 06 MF23-2 - NR
CF511C 06 MF23-2 - NR
CF285M 06 MF23-2 + NR
IATS 09 09 MF43-4 + 0-Ag, core
CF127C 09 MF43-4 + 0-Ag, core
CF305C 09 MF43-4 + 0-Ag, core
IATS 05 05 MF15-1 + 0-Ag
CF154C 05 MF15-1 + 0-Ag
CF461C 05 MF15-1 + 0-Ag
CF81M 05 MF15-1 + 0-Ag
CF681C 05 MF15-1 + 0-Ag
CF632M 05 MF15-1 + 0-Ag
CF617C 05 MF15-1 + 0-Ag
PA01 05 MF15-1 + 0-Ag
a IATS 01, 05, 06, and 09 and PA01 strains are used as positive controls,
and the last letter of clinical isolates designates the colony morphology (C,
classic; M, mucoid; R, rough). (Note: rough colony does not represent rough
LPS; see Chan et al. [8] for colony type descriptions.)
b LPS was used as the antigen. 0-Ag, MAb interacted with the ladderlike
pattern; core, MAb interacted with the core region of the LPS; NR, no
reaction.
sera in agglutination reactions. In particular, significant
cross-reactions were seen between the following groups: 02
and 05, 07 and 08, and 013 and 014 (28). Such observa-
tions were reconfirmed by us. When the same bacterial
strains were tested for cross-reactions with MAbs, only one
cross-reacting group, involving 07 and 08 strains of P.
aeruginosa, was observed. MAbs raised against IATS 07 or
IATS 08 strains agglutinated both strains. This dramatic
decrease in cross-reactions among the 0 groups clearly
demonstrated the superior specificity of MAbs over the
polyclonal rabbit sera currently used for serotyping.
Interaction of MAbs with clinical isolates from cystic fibrosis
patients. To determine whether our MAbs can be used to
type P. aeruginosa strains other than the well-defined IATS
strains, four groups of clinical isolates of serotype 01, 05,
06, and 09 were tested for their interactions with MAbs in
slide agglutination and immunoblotting experiments (Table
2). When the serotype 01-specific MAb MF25-3 was tested
against the group of 01 strains, it agglutinated all seven
strains of the group and also blotted with the ladderlike
bands of the 0 antigen of all these strains. Similar results
were obtained when the 05-specific MAb MF15-1 was tested
against eight 05 strains. The serotype 06-specific MAb
MF23-2 agglutinated all but two (strains CF651M and
CF511C) of the nine 06 strains tested. In immunoblotting
A B
200K
116K-
92K--
66K- -
45K-
31K-
G-
21.5K\ . b-H2.
14.5K .:.. ': H-2
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experiments, MF23-2 only interacted with the 0 antigen of
strain CF55C and that of the control IATS 06 strains (Table
2). MAb MF43-4, specific for serotype 09, agglutinated all
the 09 strains tested, and it also blotted with the 0 antigen
and core region of these strains.
DISCUSSION
LPS is known to be a thymus-dependent antigen that
stimulates predominantly IgM and IgG3 responses in mice
(13). However, this macromolecule in its purified form is
also a potent mitogen that will stimulate nonspecific clonal
expansion of B cells in animals. Thus, to avoid introducing
endotoxic shock or mitogenic effect in the mice, we chose to
use 107 Formalin-fixed whole cells of P. aeruginosa per
injection, as this dose did not appear to stimulate any
discernible ill effect in the animals. The hybridomas selected
and expanded produced MAbs of predominantly the IgM
class (76%, Table 1); however, LPS-specific IgG2a and IgG3
isotype MAbs were also secreted by some hybridoma
clones. For the purpose of serotyping, one would prefer to
use IgM antibodies because of their characteristic penta-
meric form and multivalent reactive (Fab) sites. From our
results, only 35% of all the IgM MAbs agglutinated homol-
ogous strains of P. aeruginosa (Table 1). Such findings
served to demonstrate the epitope specificity of the MAbs,
since only antibodies which could interact with exposed and
accessible antigenic sites on the LPS could agglutinate the
bacteria. The explanation of how these antibodies could
agglutinate homologous P. aeruginosa strains became obvi-
ous when in Western immunoblotting experiments they
interacted with the ladderlike banding patterns of the 0
antigens (Fig. 1D). Presumably, such ladderlike bands of the
0 antigen side chains of P. aeruginosa resemble the Salmo-
nella LPS bands (38) in that each adjacent band differs by
one repeating tri- to tetrasaccharide attached to the core
oligosaccharides. The antigen specificity of the group of
nonagglutinating MAbs appeared to be directed towards
epitopes other than the 0 antigen of the LPS because they
reacted with purified LPS in the ELISA but did not im-
munoblot with the ladderlike banding pattern of the 0
antigen side chains or the lower-molecular-weight rough
core bands. In addition, when outer membrane was used as
the blotting antigen, each of these MAbs interacted with all
of the major outer membrane protein bands, including pro-
tein D, protein E, protein F, protein H2, and protein I. These
antibodies cannot be outer membrane protein specific, how-
ever, because being monospecific, they would not have
interacted with all of the major outer membrane protein
bands. In addition, the antigenic uniqueness of outer mem-
brane proteins has been observed in earlier studies, in which
MAbs MA4-4 and MA1-6 reacted specifically with protein F
and protein H2 of P. aeruginosa, respectively (25, 26, 34).
The only conclusion we could draw from these observations
was that the nonagglutinating antibodies interacted with a
common LPS structure associated with all outer membrane
proteins. This assumption is supportive of the findings by
Poxton et al. (45) that outer membrane protein bands sepa-
rated on an SDS-polyacrylamide gel are actually protein-
LPS complexes. While this group of MAbs may not be useful
for serotyping, their reactivity towards an epitope associated
with all outer membrane proteins may be important for
demonstrating a common antigenic site on the cell surface.
Recently, Parr et al. (39) also reported the interaction of the
LPS-specific MAb MA6-1 with porin OmpF of Escherichia
coli. Whether such an antigenic site has any association with
the enterobacterial common antigen described by Mayer and
Schmidt (31), the P. aeruginosa "common antigen" isolated
by Hoiby and his colleagues (50), or the original endotoxin
protein reported by Abe et al. (1) has yet to be investigated.
Thus far we have produced a bank of MAbs against 12 of
the 17 IATS serotype strains of P. aeruginosa. Among these
antibodies, most agglutinate only homologous strains, in-
cluding serotype 01, 03, 05, 06, 09, 011, 012, and 014
(Table 1). Strains of serotypes 01, 05, 06, and 011 are
among the most prevalent clinical isolates from various P.
aeruginosa infections, while those of serotypes 03 and 09
are among the slightly less prevalent clinical isolates (9).
Further testing with MAbs MF25-3, MF23-2, MF15-1, and
MF43-4 has shown that these immune reagents can aggluti-
nate whole cells and immunoblot the 0 antigens of clinical
isolates of serogroups 01, 05, 06, and 09 respectively.
These data clearly establish the potential of these highly
monospecific antibodies as alternatives to rabbit sera for
typing clinical isolates (Table 2). However, the fact that only
two of the eight serotype 06 clinical strains blotted with
MF23-2 demonstrates the possible existence of subtypes
among the serotype 6 0 antigens. Similar observations were
reported in studies of E. coli LPS, in which subgroups of 01
(31) and 018 (44) LPS antigens were distinguishable by
means of MAbs.
Cross-reactions of P. aeruginosa heat-stable antigens
(predominantly 0 antigen of the LPS) with more than one of
the Difco pseudomonal typing sera are not uncommon (28).
Even after absorption, Kusama (24) still found some P.
aeruginosa strains to agglutinate with more than one
serotype-specific serum. Significantly strong cross-reactions
between serogroups 07 and 08 were observed in previous
studies (28). In fact, there were suggestions to combine these
two serogroups into one so that the IATS would consist of 16
instead of 17 serogroups. In our study with MAbs, only one
cross-reacting group among the 17 serotype strains, involv-
ing serogroups 07 and 08, was identified. Thus, 07 and 08
strains probably have a common epitope on their 0 antigens.
However, an earlier report by Knirel et al. (23) has demon-
strated that differences between Lanyi serotypes 0:3a,d and
0:3a,b differed only by ana instead of a 13 linkage between
two sugars. Such evidence suggests that one should be able
to obtain unique as well as cross-reactive MAbs against most
serotypes of P. aeruginosa. Further work is warranted to
isolate serotype-specific MAbs against each of the 07 and
08 serogroups. The fact that we could not detect more
cross-reacting groups with the MAbs demonstrates the su-
perior monospecific reactivity of these immune probes in
serotyping compared with results published previously with
polyclonal rabbit sera (28).
In conclusion, we have produced a significantly extensive
bank of MAbs against the IATS serotype strains of P.
aeruginosa. These antibodies have been characterized to
determine their serotyping potential by the standard slide
agglutination and the more sensitive Western immunoblot-
ting technique. Slide agglutination was chosen because of its
speed and simplicity and the relatively minute amount of
antibodies required per test. The feasibility of using other
techniques such as immunofluorescence, passive hemagglu-
tination and dot immunoblotting for serotyping with MAbs is
currently being investigated.
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ADDENDUM IN PRESS
While this paper was being reviewed, we learned of the
work of Gaston et al. (M. A. Gaston, T. A. Vale, B. Wright,
P. Cox, and T. L. Pitt, FEMS Microbiol. Lett. 37:357-361,
1986), who isolated a panel of 48 MAbs against eight
serotype strains of P. aeruginosa. In their study, the
isotypes and titers of the MAbs and the epitope specificity of
each MAb by Western immunoblotting were not attempted.
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